Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients.

Therapeutic drug monitoring - 1 Aug 2018

Duley John A, Ni Ming, Shannon Catherine, Norris Ross L, Sheffield Leslie, Cowley David, Harris Marion, van Kuilenburg André B P, Helsby Nuala, George Rani, Charles Bruce G

Abstract excerpt

BACKGROUND: Chemotherapy for colorectal, head and neck, and breast cancer continues to rely heavily on 5-fluorouracil and its oral prodrug capecitabine. Associations of serious fluoropyrimidine adverse effects have focused on inherited deficiency of the catabolic enzyme, dihydropyrimidine dehydrogenase. However, abnormal dihydropyrimidine dehydrogenase activity accounts for only about one-third of observed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Amidohydrolases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Capecitabine

Share to Dihydrouracil Dehydrogenase (NADP)

Share to Fluorouracil

Share to Neoplasms

Share to Phenotype

Share to Thymine

Source

Identifiers

PMID: 29846282
DOI: 10.1097/FTD.0000000000000532

Genes

DPYD
DPYS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preliminary Evidence for Enhanced Thymine Absorption: A Putative New Phenotype Associated With Fluoropyrimidine Toxicity in Cancer Patients.PMID 29846282Read ↗

Comparison of a thymine challenge test and endogenous uracil-dihydrouracil levels for assessment of fluoropyrimidine toxicity risk.Semantic proximity Read ↗

DMET™ (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity.Semantic proximity Read ↗

Thymidylate Synthase: A Target for Combination Therapy and Determinant of Chemotherapeutic Response in Colorectal CancerSemantic proximity Read ↗

Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndromeSemantic proximity Read ↗

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.Semantic proximity Read ↗

Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.Semantic proximity Read ↗

Novel opportunities for thymidylate metabolism as a therapeutic targetSemantic proximity Read ↗

In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-UreidopropionaseSemantic proximity Read ↗

The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil.Semantic proximity Read ↗

The Role of dUTPase and Uracil-DNA Repair in Cancer ChemotherapySemantic proximity Read ↗

Biochemical and clinical pharmacology of 5-fluorouracil.Semantic proximity Read ↗

Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.